Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session (ESRD Study)
Open Access
- 1 January 2021
- journal article
- research article
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 8
Abstract
Background and Objectives: There is a renewed interest in the successful use of aminoglycosides due to increasing resistance in gram-negative infections. Few studies to date have examined the pharmacokinetics (PK) of intradialytic infusions of tobramycin. This study sought to characterize the pharmacokinetic profile of intradialytically administered tobramycin in infected patients receiving chronic intermittent hemodialysis and to determine whether it is possible to achieve favorable PK targets. Design, Setting, Participants, and Measurements: In this prospective pharmacokinetic study, a single dose (5 mg/kg) of tobramycin was administered intradialytically to 11 noncritically ill patients undergoing chronic intermittent hemodialysis. Blood samples were collected at selected time to determine tobramycin serum concentrations. The PK analysis was performed using Phoenix™ NLME. The efficacy exposure outcome for nonsevere gram-negative infections sensitive to tobramycin with a minimum inhibitory concentration ≤1 were maximum concentration (Cmax ≥ 10 mg/L) and area under the curve (AUC24 h > 30 mg⋅h/L). For toxicity, the goal was to identify plasma trough concentrations max, trough levels, and AUC24h were 13.1 (1.3) mg/L, 1.32 (0.47) mg/L, and 61 (23) mg⋅h/L, respectively. Monte Carlo simulation run with 1000 virtual patients showed that a 5 mg/kg dose of tobramycin administered intradialytically can outperformed the usual low-dose postdialysis dosing (80% meeting all targets versus <1%, respectively). Conclusions: A single high dose of tobramycin can achieve favorable PK outcome when administered using intradialytic infusions in hemodialysis patients. This practical dosing regimen may represent an effective and safer alternative to the usual dosing in the treatment of nonsevere gram-negative infections.Keywords
This publication has 21 references indexed in Scilit:
- Aminoglycosides administration at the end of the hemodialysis session: A pharmacokinetic failure?Int. Journal of Clinical Pharmacology and Therapeutics, 2020
- Ototoxic effects and mechanisms of loop diureticsJournal of Otology, 2016
- Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortalityKidney International, 2016
- Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology ViewSeminars in Dialysis, 2016
- Efficacy and safety of high-dose gentamicin re-dosing in ICU patients receiving haemodialysisJournal of Antimicrobial Chemotherapy, 2014
- Gentamicin in Hemodialyzed Critical Care Patients: Early Dialysis after Administration of a High Dose Should Be ConsideredAntimicrobial Agents and Chemotherapy, 2013
- Clinical Experience with Aminoglycosides in Dialysis-Dependent Patients: Risk Factors for Mortality and Reassessment of Current Dosing PracticesAnnals of Pharmacotherapy, 2011
- Aspects of Immune Dysfunction in End-stage Renal DiseaseClinical Journal of the American Society of Nephrology, 2008
- Aminoglycoside-Induced Vestibular Injury: Maintaining a Sense of BalanceAnnals of Pharmacotherapy, 2008
- Administration of Tobramycin in the Beginning of the Hemodialysis SessionClinical Journal of the American Society of Nephrology, 2007